Market-Moving News for March 27th
$DRCT
$IBIO
$NVCR
Advertising
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $DRCT alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/16/2024 | $24.00 → $30.00 | Neutral → Buy | H.C. Wainwright | |
| 5/28/2024 | $5.00 | Buy | Chardan Capital Markets | |
| 3/27/2024 | Outperform → Market Perform | Noble Capital Markets | ||
| 11/20/2023 | $15.00 | Neutral | JP Morgan | |
| 8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright | |
| 8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler | |
| 8/4/2023 | $51.00 | Outperform | SVB Securities | |
| 7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI |
Company Launches Colossus Connections to Accelerate Direct Integration Efforts with Leading Demand-Side Platforms New Unified Buy-Side Operating Structure Creates Additional Business Lines and Revenue Opportunities Company to Host Conference Call at 5:00 PM ET Today HOUSTON, Nov. 12, 2024 /PRNewswire/ -- Direct Digital Holdings, Inc. (NASDAQ:DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP") and Orange 142, LLC ("Orange 142"), today announced financial results for the third quarter ended September 30, 2024. Mark D. Walker, Chairman and Chief Executive Officer, comm
HOUSTON, Nov. 8, 2024 /PRNewswire/ -- Direct Digital Holdings, Inc. (NASDAQ:DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP") and Orange 142, LLC ("Orange 142"), today announced that the Company will report financial results for the third quarter of fiscal year 2024 ended September 30, 2024 on Tuesday, November 12, 2024 after the U.S. stock market closes. Management will host a conference call and webcast on the same day at 5:00 PM ET to discuss the results. The live webcast and replay can be accessed at https://ir.directdigitalholdings.com/. About Direct Digital Hol
Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 Novocure (NASDAQ:NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative thera
Company's 1184% Revenue Growth Driven By Strategic & Operational Investments in Sell-Side Technology stack Inclusion Marks the Company's Second Consecutive Appearance on the List HOUSTON, Nov. 21, 2024 /PRNewswire/ -- Direct Digital Holdings ("DDH" or the "Company") ((DRCT) today announced it ranked number 101 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. In its second consecutive year on the list, Direct Digital Holdings saw 1184% growth and rose from its 108 ranking in 2023. The Company was also ranked number 3 in Texas and 23 in Di
Novocure (NASDAQ:NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas. Novocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in mouse studies as well as research identifying the optimal positioning of its newly approved Head Flexible Electrodes (HFE) transducer arrays for infratentorial brain tumors. Novocure will also present a new subgroup analysis of patients from the xCures real-world data platform that assesses the results of
New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ:NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM). Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells. Th
H.C. Wainwright upgraded NovoCure from Neutral to Buy and set a new price target of $30.00 from $24.00 previously
Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00
Noble Capital Markets downgraded Direct Digital Holdings from Outperform to Market Perform
DEFA14A - Direct Digital Holdings, Inc. (0001880613) (Filer)
DEF 14A - Direct Digital Holdings, Inc. (0001880613) (Filer)
144 - Direct Digital Holdings, Inc. (0001880613) (Subject)
SC 13G - iBio, Inc. (0001420720) (Subject)
SC 13G/A - iBio, Inc. (0001420720) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
4 - Direct Digital Holdings, Inc. (0001880613) (Issuer)
4 - Direct Digital Holdings, Inc. (0001880613) (Issuer)
4 - Direct Digital Holdings, Inc. (0001880613) (Issuer)
Brookline Capital analyst Kemp Dolliver initiates coverage on iBio (AMEX:IBIO) with a Buy rating and announces Price Target of $3.6.
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and
Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns